Hot Lots: “Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine” by Schmeling et al.

Dr. John Campbell discusses a March 2023 Danish research paper with one of the paper’s authors, Dr. Vibeke Manniche. The paper demonstrates that early batches of COVID-19 “vaccines” were associated with very high levels of adverse events.

Dr. Manniche’s research letter can be found here: https://onlinelibrary.wiley.com/doi/10.1111/eci.13998. (Schmeling, Max, et al. “Batch-Dependent Safety of the BNT162b2 mRNA COVID-19 Vaccine.” Wiley Online, 30 Mar. 2023, onlinelibrary.wiley.com/doi/10.1111/eci.13998.)

A time series analysis of United States (U.S.) government data raises similar issues.

The graph below shows a plot of a recent Centers for Disease Control and Prevention (CDC) download of the monthly number of doses administered, in orange, and the number of adverse event reports by month of injection in the Vaccine Adverse Events Reporting System (VAERS), which is maintained by the CDC and the Food and Drug Administration (FDA). The primary axis on the left shows doses administered and ranges from under 10 million in December of 2020 to over 90 million at the dosing peak in April of 2021. Adverse events, in blue, begin at 24,421 in December of 2020 and peak in March to April 2021 with over 120,000 adverse event reports per month.

1. The slope of the blue line is steeper than the orange. This indicates a rate of increase greater for adverse event reports than the rate of dosing until February 2021 when there was a data anomaly. Albert Benavides has referred to this type of anomaly as “throttling.”
2. There is close fitting of the two curves until October of 2021 when the curves diverge sharply for each of three subsequent dosing peaks.
3. The reduced (only a small increase in slope) rate of adverse event reports in the secondary, tertiary and quaternary dosing periods compared with the first suggests another type of intervention. Possibilities include a change in the formulation of the mRNA products, as discussed by Dr. Manniche, data manipulation, or something else.
4. This plot is consistent with the data discussed by Dr. Manniche through two cycles. Additional analysis of data is required for cycles three and four.

During the period from December 2020 through February 2021, Pfizer collected adverse events reports from over 40,000 people (5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021, https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf). This data was gathered during the time of the VAERS data anomaly in January to March 2021. Pfizer hired an additional 2,400 employees to handle the volume of adverse events being reported.

Originally published on Dr. Chandler’s Substack.